These results highlight the increased prevalence of cardiovascular risk factors in these patients, and the need for personalized risk assessments for cardiac complications following cardiotoxic therapies.
This data could present a non-invasive option for characterizing tumor heterogeneity to improve personalized prognosis and treatment of patients with breast cancer.
This study highlighted the need for novel therapies in myelofibrosis treatment, given that salvage therapies could potentially improve patient outcomes.
Researchers indicated the importance in improving access to and uptake of CRC screening in these underserved populations.
The drug has demonstrated the ability to reduce neutropenia induced by chemotherapy without affecting bone marrow or blood-G-CSF levels.
Although concurrent chemotherapy and radiation is considered standard care, treatment of locally advanced NSCLC continues to be challenging, leading researchers to search for patients who may benefit from the addition of cyclooxygenase 2 inhibitors.
In this study, researchers looked at the adoption and use of bevacizumab in order to identify opportunities to increase use of high-value therapies.
Researchers assessed whether ctDNA could accurately differentiate metastases during the neoadjuvant period after surgery to guide therapy adaptation.
Researchers indicated that this sort of non-pharmaceutical programming is warranted to enhance quality of life as the cancer population continues to grow.
This study provides data for consideration when discussing with patients the use of dietary supplements while undergoing chemotherapy.